全文获取类型
收费全文 | 79301篇 |
免费 | 5150篇 |
国内免费 | 3121篇 |
专业分类
耳鼻咽喉 | 545篇 |
儿科学 | 2254篇 |
妇产科学 | 1514篇 |
基础医学 | 19509篇 |
口腔科学 | 1074篇 |
临床医学 | 5575篇 |
内科学 | 16566篇 |
皮肤病学 | 1100篇 |
神经病学 | 2892篇 |
特种医学 | 1260篇 |
外国民族医学 | 7篇 |
外科学 | 3658篇 |
综合类 | 9318篇 |
现状与发展 | 19篇 |
预防医学 | 10944篇 |
眼科学 | 726篇 |
药学 | 5671篇 |
17篇 | |
中国医学 | 1173篇 |
肿瘤学 | 3750篇 |
出版年
2024年 | 76篇 |
2023年 | 876篇 |
2022年 | 2387篇 |
2021年 | 2874篇 |
2020年 | 2445篇 |
2019年 | 2201篇 |
2018年 | 2188篇 |
2017年 | 2282篇 |
2016年 | 2491篇 |
2015年 | 2891篇 |
2014年 | 4474篇 |
2013年 | 4749篇 |
2012年 | 4316篇 |
2011年 | 5144篇 |
2010年 | 4187篇 |
2009年 | 4006篇 |
2008年 | 3964篇 |
2007年 | 4027篇 |
2006年 | 3603篇 |
2005年 | 3093篇 |
2004年 | 2706篇 |
2003年 | 2417篇 |
2002年 | 1896篇 |
2001年 | 1848篇 |
2000年 | 1587篇 |
1999年 | 1420篇 |
1998年 | 1301篇 |
1997年 | 1306篇 |
1996年 | 1172篇 |
1995年 | 1182篇 |
1994年 | 1117篇 |
1993年 | 919篇 |
1992年 | 778篇 |
1991年 | 677篇 |
1990年 | 601篇 |
1989年 | 528篇 |
1988年 | 495篇 |
1987年 | 384篇 |
1986年 | 320篇 |
1985年 | 548篇 |
1984年 | 423篇 |
1983年 | 285篇 |
1982年 | 264篇 |
1981年 | 232篇 |
1980年 | 190篇 |
1979年 | 163篇 |
1978年 | 135篇 |
1977年 | 103篇 |
1976年 | 90篇 |
1974年 | 43篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2015年中华医学会感染病学分会艾滋病学组发布了第三版《艾滋病诊疗指南》。新版指南强调抗病毒治疗时点前移:一旦成人确诊感染人类免疫缺陷病毒(HIV), 若无禁忌宜尽早启动抗HIV治疗。对于合并机会性感染的HIV感染者, 在感染控制、病情稳定后也应及早开始抗病毒治疗。尤其强调HIV合并结核患者在CD4阳性淋巴细胞数少于200/μL的情况下, 建议抗结核两周内即开始抗病毒治疗。在抗HIV治疗用药中, 淘汰了一些毒副作用大、依从性较差的药物, 如司他夫定、去羟肌苷、茚地那韦等, 优选抗病毒效力强、服药方便的组合, 如拉米夫定、替诺福韦、依非韦伦组合。对于HIV感染的婴幼儿, 亦主张及早抗HIV治疗。对于五岁以内的幼儿, 主张确诊后即启动抗病毒治疗。对于HIV感染的孕产妇, 建议尽快予以全程、联合抗HIV治疗, 寓防于治。 相似文献
2.
目的:讨论普通变异型免疫缺陷病(common variable immunodeficiency disease,CVID)的发病机制、临床表现及治疗方法。方法:报道1例普通变异型免疫缺陷病合并肝硬化患者并复习相关文献。结果:普通变异型免疫缺陷病是临床少见病,易误诊,病因不清,临床表现复杂,部分患者病程中可出现肝功能异常,甚至并发肝硬化。结论:临床反复感染的患者应考虑CVID的可能,须进一步作血浆免疫球蛋白的检测确诊。对已经确诊患者定期补充静脉丙种球蛋白,同时还应定期检查肝功能。 相似文献
3.
Micro‐evolution of the hepatitis B virus genome in hepatitis B e‐antigen‐positive carriers: Comparison of genotypes B and C at various immune stages 下载免费PDF全文
4.
5.
6.
Auda A. Eltahla Fabio Luciani Peter A. White Andrew R. Lloyd Rowena A. Bull 《Viruses》2015,7(10):5206-5224
The hepatitis C virus (HCV) is a pandemic human pathogen posing a substantial health and economic burden in both developing and developed countries. Controlling the spread of HCV through behavioural prevention strategies has met with limited success and vaccine development remains slow. The development of antiviral therapeutic agents has also been challenging, primarily due to the lack of efficient cell culture and animal models for all HCV genotypes, as well as the large genetic diversity between HCV strains. On the other hand, the use of interferon-α-based treatments in combination with the guanosine analogue, ribavirin, achieved limited success, and widespread use of these therapies has been hampered by prevalent side effects. For more than a decade, the HCV RNA-dependent RNA polymerase (RdRp) has been targeted for antiviral development. Direct acting antivirals (DAA) have been identified which bind to one of at least six RdRp inhibitor-binding sites, and are now becoming a mainstay of highly effective and well tolerated antiviral treatment for HCV infection. Here we review the different classes of RdRp inhibitors and their mode of action against HCV. Furthermore, the mechanism of antiviral resistance to each class is described, including naturally occurring resistance-associated variants (RAVs) in different viral strains and genotypes. Finally, we review the impact of these RAVs on treatment outcomes with the newly developed regimens. 相似文献
7.
Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C 下载免费PDF全文
Eiichi Ogawa Norihiro Furusyo Eiji Kajiwara Hideyuki Nomura Akira Kawano Kazuhiro Takahashi Kazufumi Dohmen Takeaki Satoh Koichi Azuma Makoto Nakamuta Toshimasa Koyanagi Kazuhiro Kotoh Shinji Shimoda Jun Hayashi The Kyushu University Liver Disease Study Group 《Journal of gastroenterology and hepatology》2015,30(8):1309-1316
8.
Anna Maria Lavezzi Giulia Ottaviani Lorella Terni Luigi Matturri 《International journal of developmental neuroscience》2006,24(6):365-371
The aim of this study was to investigate the histological and biological features of the human cerebellar cortex development and differentiation. We analyzed 52 brains of fetal and infant death victims, aged from 17 gestational weeks to 12th postnatal month. In particular, in the cerebellar cortex at different ages we evaluated, besides the structural aspects, the expression of several biomarkers implicated in proliferative processes (c-fos, PCNA and apoptosis). We observed morphological patterns progressively evolving every month, from the indefinite structure of the second gestational trimester to the four-layered structure (external granular layer, molecular layer, Purkinje cell layer, internal granular layer) of the late fetal cortex and subsequently to the three-layered postnatal definitive morphology, due to involution of the external granular layer. The evaluation of the biological features of the cerebellar cortex showed high proliferative activity mainly confined to the transient external granular layer in prenatal life, and high apoptotic index after birth. Thus, the histological examination, better with the support of biomarker investigations, allows with accuracy to describe the dynamic sequence of steps that occur in human cerebellar cortex development and to establish in each case the age, namely the pre- or postnatal month of life. Consequently, we can diagnose delayed or altered processes of differentiation during the development of the human cerebellar cortex. 相似文献
9.
D Gröne† R Treudler† EM de Villiers‡ R Husak† CE Orfanos† ChC Zouboulis†§ 《Journal of the European Academy of Dermatology and Venereology》2006,20(2):202-205
Cidofovir is an acyclic nucleoside phosphonate with broad-spectrum activity against DNA viruses, including human papilloma virus (HPV). However, data on the efficacy of cidofovir in an immunosuppressive setting remain contradictory. We report for the first time on the promotion of the healing of recalcitrant warts in a patient with myelodysplastic syndrome with intravenous cidofovir treatment. 相似文献
10.
MASAFUMI IKEDA SHIGETOSHI FUJIYAMA MOTOHIKO TANAKA MICHIO SATA TATSUYA IDE HIROSHI YATSUHASHI HIROSHI WATANABE 《Journal of gastroenterology and hepatology》2006,21(1):122-128
Background and Aim: This study investigated the clinical features of hepatocellular carcinoma in patients with sustained virological response to interferon for hepatitis C viral (HCV) infection. Methods: A total of 7715 patients with HCV infection were treated with interferon and followed up for more than 1 year after withdrawal of interferon in 64 Japanese hospitals and clinics between July 1988 and August 2001. Sustained virological response was obtained in 2515 (32.6%) patients. Of these 2515 patients, clinical data were collected for 38 patients in whom hepatocellular carcinoma developed. Sustained virological response was defined as HCV RNA negativity more than 6 months after the termination of interferon. Results: All patients were HCV RNA negative at the time of diagnosis of hepatocellular carcinoma. The median period until the detection of hepatocellular carcinoma was 4.7 years (range 1.4–9.0 years). There were significant improvements in hepatic function including serum albumin, aspartate aminotransferase, alanine aminotransferase, indocyanine green test, platelet count and histological activity grade in comparison with those before interferon therapy and at the onset of hepatocellular carcinoma. The maximum tumor size in patients without medical follow‐up for 1 year or more (median: 60 mm) was significantly larger than in patients who were periodically followed up for 6 months or less (median: 25 mm) (P = 0.002). Conclusions: The present findings emphasize the importance of regular medical follow up of patients with HCV infection, as even patients showing a sustained virological response to interferon and in whom hepatic function has improved have the potential to develop hepatocellular carcinoma. 相似文献